Steroid-induced CSC may only occur in vulnerable patients

Article

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science.

For this prospective, pilot study, researchers from the Seoul National University College of Medicine and Bundang Hospital measured choroidal thickness in 35 eyes in 18 patients treated with high-dose systemic corticosteroid pulse therapy (>500 mg/d) at baseline, 1 day, 1 week and 1 month after corticosteroids were administered. Blood pressures were measured four times daily for the first 5 days of treatment as well. High-dose corticosteroid therapy concentrations delivered were 19.5 mg/kg, for a mean of 5.2 days.

At baseline, the mean subfoveal choroidal thickness was 259.8 μm (range: 86.4 to 394.7 μm). No significant changes in choroidal thickness were seen at day 1, week 1, or month 1 after treatment (P = 0.117). In only one patient who presented at baseline with pigment epithelial detachment, bilateral focal subretinal fluid was seen and showed central serous chorioretinopathy, with a 13.1% increase in subfoveal choroidal thickness.

To view an abstract of this study, click here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.